TNF and breast carcinoma: By instance, a study with breast cancer and non-Hodgkin lymphoma patients evaluated the coadministration of doxorubicin with the anti-oxidant mesna, finding that the combined regimen was able to reduce the levels of chemotherapy-induced TNF-α, TNFR and related cytokines [59].